NGHIÊN CỨU TÁC DỤNG CHỐNG XƠ GAN CỦA VIÊN NANG CỨNG TD.0072 TRÊN ĐỘNG VẬT THỰC NGHIỆM

Abstract

Research objective: Research on the anti-cirrhosis effect of hard capsule TD.0072 on white mice. Subjects and methods: Swiss white mice, both breeds, healthy, weighing 25-30 g provided by the National Institute of Hygiene and Epidemiology. Research on the anti-cirrhosis effect of TD0072 on the liver cirrhosis model by injecting mice peritoneally with 50% CCl4 solution (mixed in olive oil) with a volume of 5 μL/10 g, injecting twice a week continuously for 19 weeks. Result: There was no difference when comparing mouse liver weight between the model group and the drug groups (TD0072, silymarin). AST and ALT activities did not differ between the TD0072 oral batches and the model batches. GGT activity at both studied dose levels decreased significantly compared to the model batch (p < 0.05 and p < 0.01). TD0072 at both studied dose levels did not cause statistically significant changes in serum albumin and cholesterol concentrations compared to the model batch (p>0.05). There was no difference when compared with the model batch (p > 0.05) in MDA concentration and hydroxyproline amount. Conclusion: TD0072 at two dose levels of 1,728 g/kg/day (equivalent to the expected clinical dose) and 5,184 g/kg/day (triple dose) on an experimental model of liver cirrhosis with CCl4 showed a clear improvement in the symptoms. GGT activity index compared to the model batch, the difference was statistically significant. No differences were observed when comparing liver weights; activity indices AST, ALT; serum albumin and total cholesterol concentrations; MDA and hydroxyproline concentrations of TD0072 oral mouse batches and model batches